Making the annual eye exam quick and comfortable.
MicroStatTM is our proprietary, first-in-class fixed combination microdose formulation of phenylephrine and tropicamide for mydriasis (pupil dilation). Almost everyone who has had an eye examination has been treated with these drugs – there are an estimated 80 million office-based comprehensive and diabetic eye exams performed every year in the US.3 Eyenovia’s delivery technology is intended to make this part of the exam both faster and more comfortable for patients, by reducing the number of doses for dilation and potentially minimizing dose-related side effects (including the need to wipe away excess drug that may fall out of the eye).
3. Fernando A. Wilson, Jim P. Stimpson, and Yang Wang, “Inconsistencies Exist in National Estimates of Eye Care Services Utilization in the United States,” Journal of Ophthalmology, vol. 2015, Article ID 435606, 4 pages, 2015. https://doi.org/10.1155/2015/435606.
Learn more about our Mist-1 & 2 Study
We’re placing the power of microdosing technology in the hands of physicians and technicians. Our Mist-1 & 2 study results were presented at the ASCRS 2019 annual meeting. These results showed the efficacy and safety of the fixed combination microdose formulation and the potential for offices to improve their patient flow. Eyenovia expects to file the NDA for it’s MicroStat product in 2020.
Elevated IOP in Patients with Ocular Hypertension, Chronic Angle Closure Glaucoma, and Primary Open Angle Glaucoma
Ocular Hypertension and Glaucoma
MicroProstTM is our proprietary prostaglandin microdose formulation and candidate for the first-line treatment of ocular hypertension (OHT), chronic angle closure glaucoma (CACG), and primary open angle glaucoma (POAG). MicroProst’s MILAGRO Phase III study is expected to start at the end of 2019. If approved, this product will have the broadest indication of any once-daily glaucoma therapy currently available in the US.
Our microdosing technology may also address side effects such as loss of skin tone around the eyes and red eyes, help with poor drop instillation associated with traditional eyedropper bottles.
Learn more about our Milagro Study
We will begin our MILAGRO later in 2019. We believe the study will open a new treatment paradigm for glaucoma and ocular hypertension patients and provide eye care practitioners with a way to reduce drug and preservative exposure to sensitive tissues.
If approved, Eyenovia will have the first microdosed
treatment for progressive myopia in the United States.
Prevention of Myopia Progression
MicroPineTM is our proprietary microdose formulation of atropine and product candidate for the prevention of progressive myopia (nearsightedness) in children. Moderate-to-severe myopia is associated with a change to the shape of the eye. This change can lead to significant back-of-the eye problems, including retinal detachment, choroidal and retinal atrophy, and choroidal neovascularization, all of which can lead to permanent vision loss. 1. In the US alone, there are approximately 5 million children with myopia and many times more that number in Asia.
We believe Eyenovia’s delivery technology is particularly well-suited for this application, potentially enabling children to easily self-administer medication while minimizing dose-related side effects.
1. Theophanous, Christos et al. “Myopia prevalence and risk factors in children.” Clinical ophthalmology (Auckland, N.Z.) vol. 12 1581-1587. 29 Aug. 2018, doi:10.2147/OPTH.S164641.
Watch his nighttime routine
Low-dose Atropine and Myopia Progression
There is clinical evidence for the use of low-dose atropine as a way to prevent progressive myopia in children.2 At Eyenovia, we believe that microdosed atropine could provide similar efficacy, while our Optejet™ dispenser could provide additional usability, safety, tolerability and compliance benefits for children.
2. Chua, W., Balakrishnan, V., Chan, Y., Tong, L., Ling, Y., Quah, B., & Tan, D. (2006). Atropine for the Treatment of Childhood Myopia. Ophthalmology, 113(12), 2285-2291. doi:10.1016/j.ophtha.2006.05.062.